Current opinion on aspirin in primary prevention of atherosclerotic cardiovascular diseases. Is there any difference between diabetic and non-diabetic patients?

Abstract

Aspirin reduces vasculardeath by approximately 15% and nonfatal vascular events by about 30% in secondary prevention. The evidence in primary prevention in non-diabetic subjects is not so powerful.

The benefit of aspirin primary prevention in type 2 diabetes remains to be advocated definitely.

Keywords

• Aspirin
• cardiovasculardisease
• primary prevention
• type2diabetes